Key Highlights
- Iambic Therapeutics (NASDAQ:IAM) was quoted at USD 14.81 pre-market on Tuesday, November 10, 2026, up 10.69% from a calculated prior close of USD 13.38 set in the November 9 session.
- The stock priced its IPO at USD 16.00 on October 15, 2026, selling 9.375 million shares for USD 150 million, and opened at USD 16.15 on its first day, a gain of 13% that day.
- At the October 26, 2026 close of USD 14.41 the Market Value was USD 683.05 million on 47.40 million shares, with a 52-week range of USD 13.02 to USD 25.00 and Volume of 149,160.
- No catalyst for November 10 was identified; the company released updated IAM1363 Phase 1/1b data around October 26, and ARK Investment reportedly bought 1.18 million shares.
What Moved Iambic Therapeutics Pre-Market (+10.69%)
The pre-market snapshot before the open on November 10, 2026 shows Iambic Therapeutics at USD 14.81, up 10.69%. Simple arithmetic gives a prior close of about USD 13.38, which is 16.4% below the USD 16.00 IPO price and 7.1% below the USD 14.41 close of October 26, 2026 (both calculated). The pre-market quote is still 7.4% below the IPO price. At 47.40 million shares, USD 14.81 implies a market value near USD 702.0 million (calculated), against USD 683.05 million on October 26. Volume on October 26 was 149,160 shares, small for a company of this size, and the quote on October 27 had been USD 15.10 pre-market. The stock has therefore moved between USD 13.38 and USD 15.10 in recent sessions, a range of about 12.9% (calculated), which shows how far a single session can swing a name that listed only weeks ago. The IPO raised USD 150 million before fees, or about 21.9% of the USD 683.05 million market value (calculated).
The Rationale: Catalyst or No Catalyst
No company release dated November 9 or November 10, 2026 was found, so no catalyst is identified. The company's recent items were the USD 150 million IPO priced at the USD 15.00 to USD 17.00 range midpoint on October 15, 2026, updated clinical data for IAM1363, a brain-penetrant HER2 inhibitor, from a Phase 1/1b trial, and the reported ARK Investment purchase. General context: underwriters' research coverage normally begins after a quiet period of 25 days, which for an October 15 IPO ends on November 9, 2026 (calculated), and initiations, if any, can move a new listing. First Earnings after an IPO also draw attention, since the company would report its first quarterly results as a public company, and the September 21 and October 8, 2026 registration filings give the prior financial detail. Neither is confirmed here.
Valuation, Liquidity and Risks
The stock trades 40.8% below the 52-week high of USD 25.00 and 13.7% above the 52-week low of USD 13.02 (both calculated at USD 14.81), though that range covers only weeks of trading and the USD 25.00 high is not explained in the coverage reviewed. No analyst targets were available. The company is pre-revenue in the coverage reviewed, so valuation rests on clinical progress. Newly listed biotechs can swing widely on small volume, spreads can be wide before the 9:30 a.m. ET open, lock-up expiries can add Supply later and a clinical setback could hit the price hard. Nothing here suggests the gain will continue.
Where Things Stand
Iambic Therapeutics (NASDAQ:IAM) is up 10.69% pre-market at USD 14.81 with no identified catalyst. The quote remains below the USD 16.00 IPO price, the market value is near USD 683.05 million to USD 702.0 million and the first weeks of trading have been volatile. Thin volume means the move may reverse.



_11_17_2026_20_37_58_946960.jpg)


Please wait processing your request...